Correction, October 23, 2026: this article previously described two trials as the entire human record. FDA's 2026 assessment identifies additional studies and reported adverse events. The earlier exhaustive counts, no-event summaries and claims about unperformed testing have been withdrawn.
DSIP side effects cannot be reduced to a clean bill of health from two sleep studies. Emideltide, the name used for DSIP in FDA documents, has a broader historical human record. Some sleep studies reported favorable tolerability; a withdrawal-treatment report included adverse events. The setting and route matter. [Source]
What the human record actually includes
FDA's May 11, 2026 evaluation, prepared for the July compounding advisory meeting, summarizes intravenous exposure in 209 subjects across studies lasting one to fifteen days. This is FDA's literature summary, not a new 209-person trial or an independently deduplicated cohort count. It contradicts the earlier assertion that only two human trials exist. [Source]
The underlying papers were not independently read for this correction. Details below are attributed to the regulator's assessment and presentation. They should not be presented as a complete clinical review of every DSIP study.
Adverse events were reported, with important confounding
FDA's July 24 presentation describes a 1984 report involving 107 people treated intravenously during alcohol or opiate withdrawal. It lists nine people with transient symptoms including sweating, headache, nausea or vertigo, and three with serious adverse events. Two experienced low blood pressure at the first injection; one had recurring discomfort with sweating and nausea. The presentation also describes worsening low blood pressure after a second injection in one subject. [Source]
These observations do not establish a general-population incidence or prove that DSIP caused each event. FDA flags confounding by withdrawal symptoms and uncertainty about reported vial-solubility problems. A report of an event and a confirmed causal side effect are different findings. [Source]
Intravenous findings do not settle subcutaneous safety
The same FDA presentation says intravenous safety remains inadequately characterized and identifies no safety data for the proposed subcutaneous route. It raises potential immune-response concerns involving aggregation and peptide impurities. Those concerns are not measured rates of allergic reactions in users. [Source]
Short clinical exposure under one route cannot establish the safety of repeated self-administration, a different formulation or a combination with sleep medication. The earlier article overstated what its two cited papers could establish about tests that had never been performed. Those universal absence claims are removed.
How to read the remaining uncertainty
FDA's database search found no emideltide adverse-event reports through March 3, 2024. Its presentation explicitly cautions that missing reports do not demonstrate safety: reporting is incomplete and voluntary. That dated database result is also different from the adverse events described in the clinical literature. [Source]
For a useful DSIP safety claim, keep the population, route, follow-up and method of collecting adverse events attached. Forum experiences can reveal questions worth checking; they cannot supply a reliable frequency, establish causation or turn these historical findings into a dosing protocol.
This correction covers the source-count and safety-reporting errors on this page. The FDA briefing is an advisory assessment, not an approval or a final compounding-list determination. No treatment, dose or combination is recommended here. [Source]
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
